## Outcome of Board Meeting: Fischer Medical Ventures Limited
On October 28, 2025, Fischer Medical Ventures Limited (previously known as Fischer Chemic Limited) held a board meeting, resulting in several significant decisions that promise to impact the company's future.
### Key Highlights:
1. Financial Results Approved: The board approved the unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2025. Revenue from operations reached ₹742.69 lakhs, showing an increase compared to the previous quarter. The detailed financial results are available on the company’s [website](http://www.fischermv.com).
2. New Directorships: Mr. Chan Sing En was appointed as an Independent Director effective immediately. Additionally, the board recommended the appointment of Tan Sri Dato’ Dr. Syed Jalaludin as an Independent Director, pending shareholder approval.
3. Postal Ballot for Shareholder Consent: The board approved a postal ballot notice to seek shareholder consent for the appointment of the new independent directors.
4. Appointment of Scrutinizer: M/s Nuren Lodaya & Associates has been designated as the scrutinizer for the postal ballot, ensuring a transparent e-voting process.
The board meeting commenced at 6:00 PM and concluded at 6:45 PM IST. Fischer Medical Ventures continues to focus on growth and compliance, aligning with the SEBI regulations to enhance shareholder value.
For more information, please visit [Fischer Medical Ventures](http://www.fischermv.com).
Stay tuned for further updates from Fischer Medical Ventures as they advance their strategic initiatives in the healthcare sector.